Edison Investment Research - Acer Therapeutics Inc (OPXA) QuickView: Personalised MS immunotherapy

Report

Edison Investment Research

QuickView: Personalised MS immunotherapy

Opexa is funded through to the H216 readout of its Phase IIb Abili-T study of Tcelna in secondary progressive multiple sclerosis (SPMS). SPMS affects 30-45% of the approximately two million worldwide MS patients and an approved treatment could generate more than $5bn in US sales.

20/08/2015 2 EN

Underlying

Acer Therapeutics Inc

See profile

US68372T3014 United States

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

Edison Investment Research

Update: Moving closer towards Abili-T data in SPMS

The Abili-T Phase IIb study evaluating Opexaâ€™s Tcelna immunotherapy as a treatment for secondary progressive MS (SPMS) is nearing completion. The firm is fully funded to Phase IIb data, which are expected in early Q416 and, if positive, could sharply increase investor and stakeholder interest. Merck, the marketer of MS drug Rebif (interferon beta-1a), has an option to in-license Tcelna in MS. Our rNPV is $37.7m (vs $35.1m previously); after including $7.0m Q216 net cash, this gives an equity valuation of $44.8m.

June 29, 2016 June 29, 2016 8 EN

Edison Investment Research

Update: Restructuring sharpens focus on Tcelna data

On 2 March Opexa announced it has embarked on a restructuring initiative to prioritize its spending towards completing the ongoing 190-patient Abili-T Phase II study of lead candidate Tcelna in secondary progressive multiple sclerosis (SPMS). The company has reduced its overall headcount by about 30%, but this does not affect the Abili-T study timelines, for which data are expected in early Q416. The restructuring lengthens the companyâ€™s financial runway into Q117 (vs prior guidance of Q416), providing added flexibility around the timing of Tcelna data. Our rNPV is $35.1m, which after includ...

April 1, 2016 April 1, 2016 6 EN

Edison Investment Research

Update: Restructuring sharpens focus on Tcelna data

March 23, 2016 March 23, 2016 6 EN

Games Workshop Group - A notable acceleration in Q225

Games Workshop Group’s (GAW’s) H125 trading update suggests the company enjoyed a strong Q225 in both its core business (due to the launch of the fourth edition of Age of Sigmar midway through Q125) and licensing (due to the success of the Space Marine 2 video game). These are impressive in the context of the tough comparative from the prior year’s launch of the new edition of Warhammer 40K (40K) and the currency headwinds in the early part of H125. We upgrade our profit estimates for FY25 (by 7%) and FY26 (by 3%) to reflect the outperformance versus our prior expectations.

November 22, 2024 November 22, 2024 1 EN

Richard Williamson

Richard Williamson

Altron - Further margin expansion in H125

Altron reported a 105% y-o-y increase in operating profit before capital items in H125, with margin expansion of 5.1pp to 9.8%. The Platforms businesses were particularly strong, with Netstar and FinTech achieving material revenue and profit growth. Altron Digital Business, still in the integration phase, saw some non-recurring costs and the shift of several project starts into H225, but has seen indications that performance should improve in FY26. Management raised its FY26 operating profit target, partly to reflect the inclusion of Altron Document Solutions (ADS) in continuing operations. We...

November 22, 2024 November 22, 2024 1 EN

Alison Turner

Alison Turner

Sayona Mining - Catching up with majors

Sayona Mining is a lithium producer and explorer with projects in Canada, Western Australia and soon in the US and Ghana. A proposed merger of equals with Piedmont Lithium will create a c A$1bn mid-tier lithium player with streamlined asset ownership and significant growth optionality. Sayona and Piedmont’s Canadian and US projects comprise one of the largest advanced hard rock lithium resources in North America and are strategically positioned to supply the region’s growing lithium demand. Following the proposed equity raises, the company will be well capitalised to execute on its growth plan...

November 22, 2024 November 22, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

QuickView: Personalised MS immunotherapy

Update: Moving closer towards Abili-T data in SPMS

Update: Restructuring sharpens focus on Tcelna data

Update: Restructuring sharpens focus on Tcelna data

Games Workshop Group - A notable acceleration in Q225

Altron - Further margin expansion in H125

Sayona Mining - Catching up with majors

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe